# US 2016/0250240 A1 · Methods and compositions for promoting activity of anti-cancer therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250240 A1
- Document ID: US20160250240A1
- Status: Published application
- Kind: A1
- Application number: 15/149,961
- Filed: 2016-05-09
- Published: 2016-09-01
- Earliest claimed: 2006-08-03
- Assignees: Oncology Research International Limited
- Applicants: Oncology Research International Limited
- Inventors: Michael John Story; Kenneth Michael Wayte
- Web page: https://patentgrep.com/patent/US20160250240A1

## CPC

- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 33/243: Platinum; Compounds thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin.

## Claims

### Claim 1

A method of inhibiting growth of a cancerous cell, the method including exposing the cancerous cell to doxorubicin and a therapeutically effective amount of prosapogenin A, wherein the cancerous cell is a prostate cancer cell, a breast cancer cell, a colon cell, or a lung cancer cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method is used to inhibit formation and/or growth of a prostate, breast, colon, or lung tumor in a subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the method is used to treat a prostate, breast, colon, or lung cancer in a subject.

### Claim 4

A method of reducing a therapeutic amount of doxorubicin required for treating a cancer in a subject, comprising exposing the subject to a therapeutic amount of prosapogenin A, wherein the prosapogenin A reduces the amount of doxorubicin to which the subject is exposed.

### Claim 5 (depends on 4)

The method of claim 4, wherein the method is used to reduce the amount of doxorubicin required for treating a prostate, breast, colon, or lung cancer in a subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cancerous cell is a prostate cancer cell.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancerous cell is a breast cancer cell.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancerous cell is a colon cancer cell.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancerous cell is a lung cancer cell.

### Claim 10 (depends on 4)

The method of claim 4, wherein the cancer is prostate cancer.

### Claim 11 (depends on 4)

The method of claim 4, wherein the cancer is breast cancer.

### Claim 12 (depends on 4)

The method of claim 4, wherein the cancer is colon cancer.

### Claim 13 (depends on 4)

The method of claim 4, wherein the cancer is lung cancer.
